Interview with Michael Azrak, Managing Director, MSD South Africa
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Address: 117 – 16th Road, Halfway House, Midrand 1685,South Africa
Tel: +27 11 655 3000
From developing new therapies that treat and prevent disease to helping people in need, we’re committed to improving health and well-being around the world.
We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce.
At MSD, we’re applying our global reach and strength in scientific research to do more of what we’re passionate about: working to ensure a healthier future for all – one person at a time.
Our products cover a broad range of areas, including heart and respiratory health, infectious diseases, sun care and women’s health. And we focus our research on conditions that affect millions of people around the world – diseases like Alzheimer’s, diabetes and cancer – while building strengths in new areas like biologics.
While we work to develop innovative therapies, we also work hard to make sure they’re affordable. That’s why we offer assistance and discount programs to help make our medicines accessible to those who need them.
If we take a look at MSD’s international presence, the group has grown into the third largest pharma company in the world. Here in South Africa, you are in the…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the…
Kelly Chibale, founder of the H3D Centre at the University of Cape Town and chairman & CEO of the H3D Foundation, outlines the rationale behind the establishment of these institutions,…
Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that…
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
In a notable first, following successful pilot immunisation programmes in Ghana, Kenya and Malawi, the World Health Organization (WHO) has recommended that the RTS,S malaria vaccine be rolled out across…
A roundup of the latest news from South African pharma, including Aspen’s impressive annual growth, Adcock Ingram’s full year profit drop, and Entos Pharma’s approval for Phase II clinical rials…
With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and France – has intervened to loan South African…
The latest from South African pharma, including President Ramaphosa’s blunt criticism of Big Pharma, Aspen’s reception of USD 700 million in international financial aid, Adcock Ingram’s disappointing results as fewer…
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S, boosting the company’s share…
See our Cookie Privacy Policy Here
